Recruiting
Phase 2

Mirvetuximab Soravtansine

Sponsor:

Alessandro Santin

Code:

NCT03832361

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

IMGN853

Study Details

Brief summary:

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

Conditions

Endometrial Cancer

Study ID

NCT03832361

Start date

Jul 15, 2020

Status verified date

Jun, 2026

Completion date

Oct, 2028

Anticipated

Primary completion date

Oct, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer
  • Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed).
  • Have measurable disease
  • FRα-positive tumor expression as defined in the protocol
  • Have at least one "target lesion" to be used to assess response as defined by RECIST v1.1
  • Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed
  • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
  • Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy
  • Patients must have adequate hematologic, liver and kidney function as defined in the protocol
  • Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853
  • WCBP must have a negative pregnancy test within 4 days prior to the first dose of study treatment
  • At time of initial surgery, patient may have either been optimally or suboptimally debulked
  • Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements
  • ≥ 18 years of age

Exclusion Criteria:

  • Active or chronic corneal disorder
  • Serious concurrent illness or clinically-relevant active infection as defined in the protocol
  • Clinically-significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to day 1), unstable angina pectoris, uncontrolled congestive heart failure, uncontrolled hypertension, prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, clinically-significant vascular disease, severe aortic stenosis, clinically significant peripheral vascular disease, or cardiac toxicity following prior chemotherapy
  • History of neurological conditions
  • History of hemorrhagic or ischemic stroke within the last 6 months
  • History of cirrhotic liver disease
  • Previous clinical diagnosis of non-infectious pneumonitis
  • Prior hypersensitivity to monoclonal antibodies
  • Women who are pregnant or breast feeding
  • Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis
  • History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment
  • Required used of folate-containing supplements (e.g. folate deficiency)
  • Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: IMGN853

IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)

Interventions

IMGN853

IMGN853 6 mg/kg intravenously every 3 weeks until disease progression

Primary outcome measure

  • Objective response rate (ORR) [ Time Frame: 5 Years ]

Central Contacts and Locations

Central contacts

Alessandro D. Santin, M.D.

203-737-4450alessandro.santin@yale.edu

Lisa Baker, R.N.

203-785-6398lisa.baker@yale.edu

Locations

Smilow Cancer Hospital at Yale New Haven

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Alessandro D Santin, M.D.

203-737-4450alessandro.santin@yale.edu

Lisa Baker, R.N.

203-785-6398lisa.baker@yale.edu

Principal Investigator:

Alessandro Santin, M.D.

More Information

Sponsor

Alessandro Santin

Last update posted

Jun 26, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Alessandro Santin on 2026-06-26.